BEVACIZUMAB, BEVACIZUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, Telisotuzumab adizutecan, Lonsurf 15 mg/6.14 mg film-coated tablets
M24-064
Phase 3 small_molecule active
Quick answer
BEVACIZUMAB, BEVACIZUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, Telisotuzumab adizutecan, Lonsurf 15 mg/6.14 mg film-coated tablets for Metastatic Colorectal Cancer is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Metastatic Colorectal Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active